WuXi Biologics has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines, a JV formed by WuXi Biologics and Shanghai-based Hile Bio-Technology, estimates the value of the 20-year manufacturing contract will be over $3 billion. WuXi Vaccines expects its CDMO model will enable companies to develop and manufacture vaccines globally. More details....
Stock Symbols: (HK: 2269) (SHA: 603718)
Share this with colleagues:
Original Article: WuXi Biologics Signs LOI for $3 Billion Vaccine Manufacturing Contract